MorphoSys and Galapagos have commenced a Phase l trial to evaluate MOR106 for the treatment of moderate-to-severe atopic dermatitis.
The trial features a parallel-design and will be conducted in two parts.
In part one, healthy subjects will receive different single doses of MOR106 administered subcutaneously or intravenously. It will feature a single-centre, randomised, open-label design.
Part two will be a multiple centre, randomised, placebo-controlled, multiple-dose study. It will include patients with moderate-to-severe atopic dermatitis who will receive a subcutaneous dose of MOR106 for 12 weeks.
MorphoSys chief development officer Dr Malte Peters said: “This route of subcutaneous administration is widely used for the treatment of chronic skin diseases, and we intend to evaluate it in this study with the goal of providing support for the further clinical development of MOR106.”
MOR106 was developed using MorphoSys’ Ylanthia antibody platform and features a target discovered by Galapagos.
It is an investigational antibody directed against IL-17C, a cytokine expressed preferentially in the skin.
Galapagos chief medical officer Dr Walid Abi-Saab said: “This study represents the next important step in our strategy to progress MOR106 rapidly in the clinic and is expected to provide additional insights into patient response, while we await the results of our ongoing IGUANA Phase ll trial with MOR106 in atopic dermatitis patients.”
The IGUANA trial was started by MorphoSys and Galapagos in May this year.
The trial is designed to study MOR106 for the treatment of patients with moderate-to-severe atopic dermatitis.
It intends to enrol 180 patients, who will be treated over a 12-week period, with one of three different doses of MOR106 or placebo using two different dosing regimens across various centres in Europe.